Alumis Aktie
WKN DE: A40GLK / ISIN: US0223071020
25.03.2025 07:41:35
|
Alumis And Kaken Pharma Partner To Advance ESK-001 TYK2 Inhibitor For Dermatology In Japan
(RTTNews) - Alumis Inc. (ALMS) and Kaken Pharmaceutical Co., Ltd. announced that they have reached a collaboration and licensing agreement to develop, manufacture and commercialize ESK-001, a highly selective, next-generation oral tyrosine kinase 2 (TYK2) inhibitor, for dermatology indications in Japan, with the option to expand the license to include rheumatological and gastrointestinal diseases.
As per the terms of the agreement, Alumis will receive $40 million in upfront and near-term co-development payments in 2025 to 2026, with the potential to earn up to approximately $140 million in additional payments based on the achievement of milestones, and field option payments.
Alumis is also eligible to receive tiered royalties ranging from the low double-digits into the twenties on aggregate net sales of ESK-001 in Japan. Kaken will be responsible for the clinical development, regulatory approvals and commercialization of ESK-001 in Japan, and Alumis will retain rights to ESK-001 in all other geographies. Kaken will also contribute to a portion of the global development costs of ESK-001.

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Alumis Inc Registered shsmehr Nachrichten
Keine Nachrichten verfügbar. |
Analysen zu Alumis Inc Registered shsmehr Analysen
Aktien in diesem Artikel
Alumis Inc Registered shs | 4,06 | 1,75% |
|